Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective
The cost-effectiveness, from the Australian health care perspective, of switching patients with heart failure and reduced ejection fraction (HFREF) stable on angiotensin converting enzyme (ACE) inhibitors / angiotensin II receptor blockers (ARBs) to sacubitril/valsartan is unclear. We sought to assess the cost-effectiveness of sacubitril/valsartan versus enalapril in patients with HFREF in the contemporary Australian setting.
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Ken Lee Chin, Ella Zomer, Bing H. Wang, Danny Liew Tags: Original Article Source Type: research
More News: Australia Health | Cardiology | Diovan | Enalapril | Health Management | Heart | Heart Failure